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BACKGROUND Hidradenitis suppurativa (HS) is a chronic, inflammatory condition characterized by recurrent
nodules, sinus tracts, comedones, and scarring. Hidradenitis suppurativa is often associated with pain and
decreased quality of life. Limited clinical trial data exist regarding the management of acute HS lesions, but
clinical experience and a prospective case series suggest that intralesional triamcinolone may be useful.
OBJECTIVE To compare the efficacy of intralesional triamcinolone to placebo for the treatment of HS
inflammatory lesions.
MATERIALS AND METHODS This is a double-blind, randomized, placebo-controlled trial comparing intrale-
sional triamcinolone 10 mg/mL, triamcinolone 40 mg/mL, and normal saline (NS). Thirty-two subjects at Uni-
versity of North Carolina Dermatology and Skin Cancer Centers were enrolled for a total of 67 lesions. Subjects
reported pain scores, days to resolution, and satisfaction on a standardized survey over a 14-day period.
RESULTS When intralesional injections of triamcinolone 10 mg/mL, triamcinolone 40 mg/mL, and NS were
compared, no significant difference was found for days to HS inflammatory lesion clearance, pain reduction at
Day 5, or patient satisfaction.
CONCLUSION No statistically significant difference was found between varying concentrations of tri-
amcinolone and NS for the treatment of HS lesions. Steroid injections may be less effective for the manage-
ment of acute HS than typically presumed.
The authors have indicated no significant interest with commercial supporters. Institutional review board
approval: reviewed and approved by UNC IRB; approval #16-0773. Clinicaltrials.gov listing: NCT02781818.
Hidradenitis suppurativa (HS) is a dermatologiccondition characterized by painful, recurrent
inflammatory nodules and sinus tracts with a
prevalence of 0.05% to 4%.1,2 In severe cases,
secondary lesions including rope-like scarring,
plaque-like induration, and multihead comedones
may be present.3 The affected skin is primarily located
in the axilla, inframammary and intermammary
folds, and the inguinal and anogenital regions.3 The
average age of onset for HS is in the early twenties
with an average delay in diagnosis of 5 to 14 years.3–5
In a survey, individualswithHS reported an average of
2 new inflammatory nodules per month, lasting an
average of 6.9 days.5 In another study, 65%of patients
sought out medical attention for pain control due to
HS flares.6 When assessing how HS impacts daily life,
patients reported that the worst aspects of living
with the disease are pain, restriction of daily activities,
lack of intimacy due to location of lesions, and
lesion malodor. Unfortunately, the hardships
associated with HS lead to approximately half of
patients experiencing a psychiatric comorbidity
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Hill, NC, and Hillsborough, NC. This study was
approved by the UNC Institutional Review Board,
and all patients provided written informed consent
before enrollment.
Study Population
Patients at routine office visits were eligible for this
study if theywere at least 16 years old, experiencing an
acutely inflamed nodule, either on no antibiotics or
on a stable course for at least 4 weeks before the visit,
and had at least a year-long history of HS symptoms.
Acceptable antibiotics included topical clindamycin,
topical chlorhexidine gluconate, oral doxycycline,
oral minocycline, or oral clindamycin with or without
rifampin. Patients who were unable to provide
informed consent, or informed assent for those
younger than 18 years with guardian consent, were
excluded from the study. Discrete, painful lesions less
than 2 centimeters in size with signs of active inflam-
mation were identified by a dermatologist who spe-
cializes in HS (Figure 1). A maximum of 3 nodules per
person could be included. At enrollment, information
was collected on disease history, and the HS specialist
assessed severity of the disease based on Hurley Stage
and number of nodules and sinuses in the area to be
injected. Hurley 1 disease is limited to inflammatory
nodules, Hurley 2 includes disease that has progressed
to the formation of sinus tracts, and Hurley 3 involves
interconnecting sinus tracts in multiple areas.
Treatment
The treatment arms were 0.1 mL of nonbacteriostatic
0.9% sodium chloride, TAC10, and triamcinolone 40
mg/mL (TAC40). The volume of 0.1 mL was chosen
because it is consistent with standard practice at UNC
Figure 1. Typical discrete inflammatory nodules included
in the study (arrows).
with an increased risk of depression, anxiety, and 
suicide.7,8
Hidradenitis suppurativa is understood to be an 
inflammatory disease affecting follicular units, rather 
than an infectious process. Early lesions characteris-
tically show normal bacterial skin flora, suggesting 
that bacterial growth in chronically inflamed nodules 
is a secondary process.9 The initial lesions seem to 
involve perifollicular infiltration of IL-1, IL-10, 
IL-17, tumor necrosis factor, S100A8, S100A9, and 
caspase-1. Neutrophils, monocytes, and mast cells 
are also prevalent.10–15 It is proposed that the 
inflammatory process is perpetuated by the spillage 
of follicular contents into surrounding tissue. 
Tunneling and scar formation occur during the 
healing process.10
Treatment options for HS range from topical anti-
biotics and monoclonal antibodies to surgical exci-
sions. Data supporting management of HS flares are 
lacking, but intralesional triamcinolone is commonly 
used for the treatment of acute lesions.10 A national 
database of patients with HS demonstrated that 6.7%
received triamcinolone for treatment.16 Topical ste-
roids were the third most common treatment for HS, 
behind antibiotics and pain medications. A pro-
spective case series assessed the efficacy of intrale-
sional triamcinolone 10 mg/mL (TAC10) in the 
treatment of HS flares. A significant reduction in pain 
1 day after injection was found, as well as a decline in 
erythema, edema, suppuration, and lesion size after 
1 week.17 The absence of a placebo control was a 
major limitation of this study. To strengthen the data 
on intralesional triamcinolone for the treatment of 
acute HS, a trial was conducted to compare tri-
amcinolone with normal saline (NS) placebo.
Methods
This is a randomized, double-blind, placebo-
controlled trial assessing the efficacy of intralesional 
triamcinolone at resolving lesions and reducing pain 
in patients experiencing an acute HS flare. Patients 
were recruited at HS subspecialty clinics at Univer-
sity of North Carolina at Chapel Hill (UNC) 
Dermatology and Skin Cancer Centers in Chapel
for treatment of discrete HS lesions and does not
create afield effect. Lesionswere randomized in a1:1:1
ratio to one of the treatment arms by the coinvestiga-
tor. The coinvestigator prepared syringes and covered
them with opaque tape to maintain blinding for sub-
jects and the principal investigator who performed the
injections.
Subjects were asked to rate the pain of each ran-
domized lesion on a scale from 1 to 10 before
intervention. The subjects received a paper ques-
tionnaire to complete for each lesion on post-
treatment days 1, 2, 3, 5, 7, 10, and 14. Subjects were
instructed to rate the pain associated with each
lesion on the specified days and note whether it had
resolved. Lesion resolution was defined on the
questionnaire as “when the pain is gone and the
lesion has returned to how it was before it became
inflamed.” On Day 14, subjects indicated whether
the intervention “made it worse,” was “not help-
ful,” “a little bit helpful,” “moderately helpful,” or
“very helpful.” Subjects were instructed to mail in
their questionnaires after completion.
Sample Size Calculation
The primary outcomes evaluatedwere average days to
resolution of lesions and reduction of the associated
pain 5 days after intervention. Pain reduction was
calculated by subtracting the Day 5 pain score from
the preintervention pain score. With 60 lesions, the
studywas powered at 80% to detect a 3-day difference
betweenNS and the total groupof lesions that received
triamcinolone (TAC) consisting of TAC10 plus
TAC40 and powered at 100% to detect a 3-point
difference between pain score reduction at Day 5.
With 50 lesions, the power became 64% and 100%,
respectively. In addition, TAC10 versus TAC40 was
assessed.
Data Analysis
SAS 9.4 was used for all analyses. In the descriptive
analysis,meanvalues,95%confidence intervals (CI), and
p-values were calculated for NS, TAC10, TAC40, and
TAC for each outcome. Survival analysis based on the
gamma frailty model was used to compare days to
resolution. In the multivariate analysis, linear mixed-
effect models were used for the outcomes of pain reduc-
tion and satisfaction to assess and account for potential
correlation with demographics, lesions treated in the
same patient, location of nodules, number of sinuses and
nodules in the injected region, and Hurley stage.
Results
Subjects
Between June 2016 and May 2017, 32 patients were
enrolled for a total of 67 lesions. In all, 21 lesions were
enrolled in the NS arm, 24 lesions were enrolled in the
TAC10 arm, and 22 lesions were enrolled in the
TAC40 arm (Figure 2). Five subjects were lost to
follow-up, which resulted in loss of data for 9 lesions.
Fifty-eight lesions had at least partial completionof the
survey and were ultimately included in the analysis.
The participants were 36 years old on average and
95%female, 50%AfricanAmerican, 45%Caucasian,
and 5%Hispanic. Literature suggests that the highest
disease prevalence is among women and African
Americans.1 Subjects had an average disease duration
of 13.5 years and Hurley Stage of 2.25. Baseline
characteristics were similar across interventions and
had no significant effect on the outcomes. Moderate
correlations were found among lesions on the same
subject, so this was accounted for in the analysis.
Lesion Resolution
Lesions injected with NS had an average resolution of
9.35 days (95% CI: 6.87–11.83), TAC10 averaged
10.78 days (95% CI: 8.16–13.4), TAC40 averaged
10.85 days (95%CI: 8.32–12.38), and TAC averaged
Figure 2. Enrollment and analysis flow diagram.
Five days after intervention, lesions injected with NS
had an average pain score reduction of 2.63 (95%
CI: 1.40–3.86), IL TAC 10 had a 2.00 reduction
(95%CI: 0.65–3.35), IL TAC 40 had a 2.30 reduction
(95% CI: 1.14–3.46), and TAC arm had a reduction
of 2.16 (95% CI: 1.32–3.00). When comparing
TAC with NS, there was no statistically significant
difference, p = .77 (Figure 4). All interventions
followed a very similar downward trend in pain
over the 14 days (Figure 5).
Patient Satisfaction
All interventions were typically found to be “a little bit
helpful” to “moderately helpful” (Figure 6). When
comparing TAC with NS, there was no statistically
significant difference, p = .54.
Adverse Events
No subjects reported adverse events.
Discussion
Contrary to the authors’ expectations, this study
was unable to find a statistically significant differ-
ence between 0.1 mL of TAC and NS for the
treatment of acute HS lesions over a 14-day period.
There was also no difference found between TAC10
and TAC40. Since subjects on average found
injections to be at least “a little bit helpful,” it is
possible that the act of puncturing a lesion or
instilling external solution provides some relief.
Average resolution of lesions and the pain score
trends were very similar across interventions, which
suggests that lesions haveanatural courseof resolution.
This is consistentwithfindings inapreviousprospective
study that demonstrated improvement of pain in the
days following treatment with TAC10.7 Moving for-
ward, it would be helpful to note the number of days
that a lesion has been inflamed before intervention to
see if that influences the degree of benefit patients
receive from injections.
A limitation of the study is that the number of injec-
tions and volume usedmay not reflect other clinicians’
typical use. Benefits seen anecdotally may be due to an
injection of higher overall volumes. In addition, data
Figure 4. Mean pain reduction 5 days after injection for nor-
mal saline, intralesional triamcinolone 10mg/mL, intralesional
triamcinolone 40 mg/mL, and the average of intralesional
triamcinolone 10 mg/mL and intralesional triamcinolone
40mg/mL. IL TAC 10, intralesional triamcinolone 10mg/mL; IL
TAC 40, intralesional triamcinolone 40 mg/mL; IL TAC,
intralesional triamcinolone; NS, normal saline.
Figure 5. Pain trend using average pain scores on 0, 1, 2, 3,
5, 7, 10, and 14 days after intervention. IL TAC 10, intrale-
sional triamcinolone 10 mg/mL; IL TAC 40, intralesional
triamcinolone 40 mg/mL; NS, normal saline.
10.82 days (95% CI: 9.26–12.38). When comparing 
TAC with NS, there was no statistically significant 
difference between the interventions, p = .44
(Figure 3).
Pain Reduction
Figure 3. Average days to resolution after injection for 
normal saline, intralesional triamcinolone 10 mg/mL, 
intralesional triamcinolone 40 mg/mL, and the average of 
intralesional triamcinolone 10 mg/mL and intralesional 
triamcinolone 40 mg/mL. IL TAC 10, intralesional tri-
amcinolone 10 mg/mL; IL TAC 40, intralesional tri-
amcinolone 40 mg/mL; IL TAC, intralesional triamcinolone; 
NS, normal saline.
were collected on 58 lesions rather than 60 due to time
constraints and loss to follow-up. Although this was
slightly below the goal, the study remained well-
powered to detect improvement in pain scores and
moderately powered to identify improvement in days
to lesion resolution.
Considering the results and potential discomfort, side
effects, time, and monetary cost, TAC may not be
justified for all patients with HS. Physicians should be
guided by their clinical judgment and individual
patient’s preferences. Larger studies with varying
volumes of TAC should be considered in the future.
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Figure 6. Patient satisfaction 14 days after injection for
normal saline, intralesional triamcinolone 10 mg/mL,
intralesional triamcinolone 40 mg/mL, and the average of
intralesional triamcinolone 10 mg/mL and intralesional
triamcinolone 40 mg/mL. IL TAC 10, intralesional tri-
amcinolone 10 mg/mL; IL TAC 40, intralesional tri-
amcinolone 40 mg/mL; IL TAC, intralesional triamcinolone;
NS, normal saline.
